
"Good Days Are Over": Chinese Students After Trump's Crackdown On Visas
Beijing:
Chinese students with offers from US universities expressed despair after Washington promised to start "aggressively" revoking Chinese student visas and ordered US missions abroad to stop scheduling new student visa appointments.
If applied to a broad segment of the 277,000 Chinese students already at US colleges, the move could disrupt a major source of income for universities and a crucial pipeline of talent for US technology companies as the Trump administration pursues its hardline immigration agenda.
"It's pretty absurd. It doesn't seem like something that should happen these days. I scrolled social media and felt quite anxious seeing other people's reactions," said Chen, 22, who has a postgraduate offer to study a humanities subject from the University of North Carolina, Chapel Hill.
"Although my major is not sensitive, my visa application process hasn't started yet and my course begins in early August."
Chen, who lives in the southwestern megacity of Chengdu, is prepared to defer her studies for a term if the visa doesn't come through in time. She preferred not to share her full name for privacy reasons.
"If I really can't go to the US, I may take up an offer from the UK's London School of Economics," she said.
Reuters reported that US Secretary of State Marco Rubio asked his department to pause the scheduling of student visa appointments until the department issues updated guidance on social media vetting of applicants.
The news set off a wave of confusion and despair on China's Instagram-like platform RedNote, as incoming students scrambled to book the last remaining visa interview slots and others complained that they could no longer book.
Wu said she stayed up until 3 a.m. on Wednesday frantically refreshing the webpage until she managed to snag a precious mid-June interview slot at the US Consulate in Shanghai.
"At nearly midnight I saw the news and immediately started booking, the page crashed several times," she told Reuters.
The 29-year-old biology student, who preferred not to share her full name for privacy reasons, has an offer from the University of Minnesota Duluth and no back-up plan if her visa is rejected.
The cable, signed by Rubio, said previously scheduled appointments may proceed but did not specify when the interview booking system would resume. Nor did Rubio specify when the visa revocations would begin.
"The Department's scheduling of nonimmigrant visa interview appointments is dynamic," a State Department spokesperson said in response to Reuters' questions about the suspension of appointments.
"Visa applicants may continue to submit applications. Consular sections constantly adjust their schedules to allow for sufficient time to fully vet the cases before them."
The spokesperson added that the Trump administration was focused on "upholding the highest standards of national security and public safety through our visa process."
Running out of time
The announcement comes at a critical period in the international student application process, as many young people prepare to travel to the US in August to find accommodation and settle in before term starts.
"I was super looking forward to starting my university life but then all this happened," said a Beijing high school senior with a media studies offer from Ohio State University, who declined to give her name for privacy reasons.
"I still need 1-2 months to apply for my visa, term starts soon and I have no time left, it's really a disaster out of nowhere and really unfair to international students."
In their posts on RedNote, a few Chinese social media users also reported additional scrutiny of their listed social media accounts from US consular officials during visa interviews this week.
In Beijing, the foreign ministry condemned the measures against Chinese students and said it had lodged protests with the US
"The US side, using ideology and national security as an excuse, irrationally revoked Chinese international student visas," Chinese foreign ministry spokesperson Mao Ning said at a briefing on Thursday.
"Its politically discriminatory practices pierce through the so-called freedom of speech it has always flaunted, this will only further damage its international image and reputation."
China is also at the epicentre of Trump's global trade war that has roiled financial markets, upended supply chains and fuelled risks of a global economic downturn. The decision to cancel Chinese student visas is happening despite a recent pause in the US-China trade dispute.
International students - 54% of them from India and China - contributed more than $50 billion to the US economy in 2023, according to the US Department of Commerce.
"It is superpower suicide to stop the best foreign minds from coming to the United States and using their talents to propel American prosperity and technological advantage," Rush Doshi, a former Biden administration China official and assistant professor at Georgetown University, wrote on X on Wednesday.
"The iron fist has come down," wrote an anonymous Chinese PhD student at the University of Wisconsin, Madison on RedNote on Thursday.
"The good days are over and a new round of hard times will begin for international students."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indian Express
27 minutes ago
- Indian Express
‘Not talking, not paying': Trump rejects Iran deal, blasts Democrats
In a blistering Truth Social post, US President Donald Trump on Monday tore into Democrat Senator Chris Coons, insisting he's made no offers to Iran and certainly no payments, unlike former President Barack Obama. He also said that his administration is not in talks with Iran and categorically denied any proposal to support Tehran's nuclear programme. 'We're not speaking to Iran,' Trump wrote, adding, 'We're not offering them anything.' Trump's comments come amid ongoing debate over the state of Iran's nuclear programme following US and Israeli military strikes earlier this month. The president repeated his previous assertion that the US had 'totally OBLITERATED' Tehran's nuclear facilities, calling media reports about ongoing negotiations a 'hoax'. In an interview with Fox News on Sunday, Trump elaborated on the nature of the strikes, specifically at Iran's Fordo nuclear site. 'They questioned whether the sites were 'obliterated' or just terrible, and it turned out that they were in fact obliterated,' he said, adding that the bombs 'penetrated like absolute butter.' Independent satellite imagery and Israeli intelligence assessments cited in multiple media outlets have supported claims of extensive structural damage at several nuclear facilities. Trump also took aim at reports suggesting his administration had considered offering Iran up to $30 billion in aid to build a civilian nuclear energy programme. He strongly denied the existence of any such deal. The president has often criticised the 2015 Joint Comprehensive Plan of Action (JCPOA)—commonly known as the Iran nuclear deal—brokered under Barack Obama, which lifted sanctions on Iran in exchange for limits on its nuclear activities. Trump withdrew the US from the JCPOA in 2018, calling it a 'disaster.' The post also targeted Senator Chris Coons, a Democrat from Delaware and vocal critic of Trump's Iran policy. Coons has publicly raised concerns about the lack of congressional oversight in Trump's recent military actions against Iran and has urged diplomatic engagement. In his post, Trump labeled Coons 'phony' and rejected any notion of behind-the-scenes talks.


Fashion Value Chain
35 minutes ago
- Fashion Value Chain
NBA & Skechers Drop Season 2 of Hoop Nation in India
The NBA, in collaboration with Skechers, has officially launched Season 2 of Hoop Nation—a four-part docuseries celebrating India's grassroots basketball stories through the powerful medium of lyrical hip-hop. The docuseries is streaming on the NBA India YouTube channel (@NBAIndiaOfficial) with bonus music videos. Presented by Skechers, this season explores inspiring journeys of basketball players and mentors from across India: Ishrat Akhter , a wheelchair basketball athlete from Baramulla, Kashmir Deepak P. Babu , a Kerala-based mentor and content creator The Lao family , a father-daughter duo from Kolkata's Indo-Chinese community Farooque Shaikh, a youth coach from Nagpada, Mumbai All participants are seen sporting Skechers Basketball footwear, showcasing the brand's performance innovation and comfort. Each story is brought to life through original music by Indian hip-hop artists, including: Straight Outta Srinagar (SOS) from Kashmir ThirumaLi , a Malayalam rap icon EPR Iyer , a Kolkata-based hip-hop veteran QK, Mumbai's breakout rapper-singer Through original verses and beats, these artists narrate the triumphs, challenges, and community impact of the basketball journeys featured in the series. Rajah Chaudhry, Head of NBA India, noted that the series reflects the game's deep emotional and cultural connection with Indian youth. He emphasized the league's partnership with Skechers as a shared mission to grow the sport locally. Rahul Vira, CEO of Skechers South Asia, echoed this sentiment: 'Our continued collaboration with the NBA through Hoop Nation and the ACG Jr. NBA program supports our mission to empower young talent and provide them with elite-level gear.' Beyond content, Skechers also supports basketball development in India. The brand served as the official kit partner for the ACG Jr. NBA Program, India's largest U-14 school-based basketball initiative, which engaged over 4,000 students from 500+ schools last year. With this partnership, NBA and Skechers aim to inspire communities, drive long-term impact, and highlight India's growing basketball culture.

Mint
37 minutes ago
- Mint
India's Pharma sector falters in H1 2025; index falls over 6% becoming the second worst-performing sector
India's pharmaceutical sector has come under significant pressure in 2025, with the Nifty Pharma index falling more than 6 percent during the first half of the year. In stark contrast, the broader Nifty 50 index gained nearly 8 percent over the same period. Investor sentiment has turned sharply bearish amid a series of domestic and global concerns ranging from export tariffs to macroeconomic uncertainty. The downturn has been broad-based. Natco Pharma suffered the steepest decline, plunging around 34 percent. IPCA Labs dropped over 20 percent, while Aurobindo Pharma, Lupin, Granules India, Mankind Pharma, Ajanta Pharma, and Alkem Labs lost between 12–20 percent. Even stalwarts such as Biocon, Cipla, Dr Reddy's, JB Chemicals, and Sun Pharma saw setbacks of 1–10 percent. Amid the decline, a few companies have stood out. Laurus Labs recorded a 19 percent gain, Abbott India rose 16 percent, Divi's Labs climbed 10 percent, and Glenmark Pharma increased by 8.6 percent. Torrent Pharma and Zydus Life also managed modest gains. The sector's weakening fortunes are linked to several concerns. Large-scale foreign institutional investor (FII) exits, particularly from export-sensitive industries, have weighed heavily on pharma stocks. Macro risks such as sluggish global growth, higher interest rates, and the ongoing US–China trade tensions have exacerbated the situation. Market anxiety escalated after former US President Trump's announcements—first in April and again in June—hinting at enforcing pharmaceutical tariffs of up to 25 percent. Such measures would severely impact Indian drugmakers, which export up to 40 percent of their generics and specialty medicines to the US. Nuvama Institutional Equities acknowledged investor caution surrounding large-cap pharma, particularly due to US policy threats and product-mix exposure. It noted, however, that interest remains strong in CDMOs and GLP‑1 drug manufacturers, while healthcare services appear poised for double-digit growth thanks to facility expansions. Tariff and product-mix concerns: Nuvama flagged persistent worries about a potential shift in US import policy, which could impose higher duties on Indian generics such as gRevlimid, gMyrbetriq, gSpiriva, gJynarque, and Lanreotide. The next two months are seen as pivotal for potential rule changes. It added that Cipla's strong pipeline—featuring products like gAbraxane and gSymbicort—and market-share gains in Lanreotide may calm investor fears. Sustained interest in CDMO and GLP‑1 space: Despite US export uncertainty, investors are positive about CDMOs. Firms like Aarti Pharmalabs have benefitted from production shifts from China. Jubilant Pharmova, Divi's, and Dr Reddy's continue to prosper, supported by growth in fill-finish services and GLP‑1 demand—what Nuvama described as 'near-term opportunities.' Optimism in healthcare services: Nuvama also sees promise in healthcare infrastructure. Companies like Laxmi Dental, Jupiter Lifeline, Suraksha, Aster DM, and Jeena Sikho are expanding inpatient capacity and operating efficiently. New centres and investments in diagnostics, digital tools, and hospital beds are expected to underpin robust revenue and margin growth. Nuvama's Top Picks & Emerging Themes Analyzing their coverage, Nuvama identified several names with strong potential: Aurobindo Pharma ('Buy', ₹ 1,460 TP): Valued at around 14× FY27E EPS, its Pen‑G facility restart and pipeline investments in biologics and peptides are likely to drive growth. Jubilant Pharmova ('Buy', ₹ 1,385 TP): Positioned to benefit from re‑shoring trends in US manufacturing and sustained demand for CDMO services. Lupin ('Buy', ₹ 2,570 TP): With key US launches including gSpiriva and gXarelto, its FY26 PAT growth projection of 19 percent underpins a strong outlook. Laxmi Dental ('Buy', ₹ 530 TP): Laxmi is gaining from underpenetrated oral health markets, digital dental tools, and export growth in aligners. Jupiter Lifeline ('Buy', ₹ 1,800 TP): On track to double bed capacity with greenfield expansions and ramp up revenue through capacity utilisation. Aarti Pharma: Benefiting from new CDMO projects and expanded intermediate capabilities. Eris Life: Positioned to leverage insulin and GLP‑1 demand, expected to reach PHY26 profitability inflection. OneSource Specialty: Peptide and biologics CDMO poised for early commercial launches. Shilpa Medicare: Focusing on niche and high-value products like 505b2 and ADCs. Aster DM: With bed expansions and merger synergies, set to become a top-tier hospital chain. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.